Clinical Trial Update: Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).

View source ↗

Summary

Pfizer completed a long-term post-marketing safety investigation of tolterodine for overactive bladder; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Detrol (tolterodine)

Snippet

Sponsor: Pfizer | Conditions: Urinary Bladder, Overactive | Status: COMPLETED | Results posted: 2012-07-09